Aytu BioPharma secures exclusive U.S. commercialization rights to EXXUA (gepirone) for MDD

AYTU BIOPHARMA, INC

• Upfront cash payment of $3M; second payment of $3M due 1-year post-launch, increasing to $5M if first-year net sales exceed $35M.
• Royalty on net sales starts at 28%, steps up to 39% when annual net sales surpass $300M; lower tier after trigger at 24.5%-35.5%.
• Milestone payments range from $5M to over $100M per year based on net sales thresholds; 10% royalty on sales above $1B.
• EXXUA is a first-in-class 5HT1a receptor agonist for MDD with no sexual dysfunction label warning; launch targeted for Q4 2025.
• Transaction funded by cash on hand and institutional investors including Nantahala Capital, Stonepine Capital, and Aytu management.